Results 241 to 250 of about 2,223,665 (257)

Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma

2017
Sorafenib is the first-line systemic treatment in hepatocellular carcinoma (HCC). The benefits of sorafenib in HCC show an improvement in overall survival and delay of radiologic tumor progression. These benefits were demonstrated in the absence of a high rate of overall response and the magnitude of this improvement varies considerably from patient to
Maria Reig, Álvaro Díaz-Gonzalez, Andrea Ribeiro, Anna Darnell   +3 more
openaire   +1 more source

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report

Medical Oncology, 2008
Platinum-based chemotherapy regimens are often recommended for patients with unresectable thymic carcinoma. In more than 60 cases, however, the systemic chemotherapy provides little benefit. In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a
Xiao-Feng, Li, Qiang, Chen, Wei-Xian, Huang, Yun-Bin, Ye   +3 more
openaire   +2 more sources

Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Sorafenib is a cornerstone in the treatment of advanced HCC. However, its clinical efficacy is frequently limited by the development of resistance, contributing to unfavorable patient outcomes. Overcoming this resistance is therefore a critical therapeutic challenge. Emerging evidence highlights ferroptosis-a regulated cell death process driven by iron-
Linlin, Che, Liujing, Zhu, Ling, Zhou, Yufu, Zhou   +3 more
openaire   +2 more sources

Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy

European Journal of Pharmacology, 2023
Kexin Chen, Qiuhong Li, Jun Jiang
exaly  

Targeting glucosylceramide synthase increases sorafenib efficacy and evades sorafenib resistance in HCC models

2017
Trabajo presentado en el 50th International Liver Congress, celebrado en Viena, Austria, del 22 al 26 de abril de ...
Stefanovic, Milica, Tutusaus, Anna, Bárcena, Cristina, Martínez-Nieto, Guillermo A., Marí, Montserrat, García-Ruiz, Carmen, Fernández-Checa, José C., Morales, Albert   +7 more
openaire   +1 more source

Sorafenib resistance of hepatocellular carcinoma

2020
openaire   +1 more source

Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma

Biomedicine and Pharmacotherapy, 2023
Chunxiao Li, Junjie Wang, Shuhua Wei
exaly  

S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway

Cell Reports, 2022
Dianyun Ren, Heshui Wu
exaly  

New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies

Biochimica Et Biophysica Acta: Reviews on Cancer, 2017
George Chen, Sheng-Li Yang, Niu Lei
exaly  

SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma

Biomedicine and Pharmacotherapy, 2020
Xiaoyuan Zi, Yun Yang, Xiaosong Zhi
exaly